Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Anderegg, T. R.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderegg, T. R.
Right arrow Articles by Jones, R. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 1019-1021
© 2002 The British Society for Antimicrobial Chemotherapy

In vitro evaluation of AZD2563, a new oxazolidinone, tested against ß-haemolytic and viridans group streptococci

Tamara R. Anderegg1, Douglas J. Biedenbach1 and Ronald N. Jones1,2,*

1The Jones Group/JMI Laboratories, North Liberty, IA; 2Tufts University School of Medicine, Boston, MA, USA

Received 25 October 2001; returned 21 January 2002; revised 21 February 2001; accepted 26 February 2002.

Linezolid was the first clinically applied agent from the oxazolidinone class, and AZD2563, a new agent, is described here. Five hundred and twenty-five streptococcal isolates were tested, including ß-haemolytic (266) and viridans group (259) species. MIC50/MIC90/% susceptible (susceptibility breakpoint <2 mg/L of AZD2563) results were, for ß-haemolytic species: AZD2563 (1/2/100), linezolid (1/2/100), quinupristin–dalfopristin (0.25/0.25/100), vancomycin (0.25/0.5/100) and levofloxacin (0.5/1/99); for viridans group species: AZD2563 (0.5/1/100), linezolid (1/1/100), quinupristin–dalfopristin (0.5/1/99), vancomycin (0.5/0.5/100) and levofloxacin (1/1/98). The modal MICs of AZD2563 and linezolid were 0.5 or 1 mg/L and 1 mg/L, respectively. AZD2563 activity screening against these non-pneumococcal streptococci indicated a slightly greater potency of AZD2563 when compared with linezolid. All AZD2563 MICs were <2 mg/L.

* Correspondence address. JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. Tel: +1-319-665-3370; Fax: +1-319-665-3371; E-mail: ronald-jones{at}jmilabs.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
H. Seppala, M. Haanpera, M. Al-Juhaish, H. Jarvinen, J. Jalava, and P. Huovinen
Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora
J. Antimicrob. Chemother., October 1, 2003; 52(4): 636 - 644.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P.-R. Hsueh, L.-J. Teng, C.-M. Lee, W.-K. Huang, T.-L. Wu, J.-H. Wan, D. Yang, J.-M. Shyr, Y.-C. Chuang, J.-J. Yan, et al.
Telithromycin and Quinupristin-Dalfopristin Resistance in Clinical Isolates of Streptococcus pyogenes: SMART Program 2001 Data
Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2152 - 2157.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.